Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Nurix Therapeutics (NRIX) Return on Equity: 2020-2025

Historic Return on Equity for Nurix Therapeutics (NRIX) over the last 5 years, with Aug 2025 value amounting to -0.60%.

  • Nurix Therapeutics' Return on Equity fell 12.00% to -0.60% in Q3 2025 from the same period last year, while for Aug 2025 it was -0.60%, marking a year-over-year decrease of 12.00%. This contributed to the annual value of -0.53% for FY2024, which is 4.00% up from last year.
  • Nurix Therapeutics' Return on Equity amounted to -0.60% in Q3 2025, which was down 33.72% from -0.45% recorded in Q2 2025.
  • In the past 5 years, Nurix Therapeutics' Return on Equity registered a high of -0.20% during Q1 2021, and its lowest value of -0.78% during Q1 2024.
  • For the 3-year period, Nurix Therapeutics' Return on Equity averaged around -0.57%, with its median value being -0.60% (2025).
  • As far as peak fluctuations go, Nurix Therapeutics' Return on Equity slumped by 31bps in 2022, and later skyrocketed by 37bps in 2025.
  • Quarterly analysis of 5 years shows Nurix Therapeutics' Return on Equity stood at -0.33% in 2021, then dropped by 23bps to -0.56% in 2022, then declined by 10bps to -0.66% in 2023, then grew by 23bps to -0.43% in 2024, then dropped by 12bps to -0.60% in 2025.
  • Its Return on Equity was -0.60% in Q3 2025, compared to -0.45% in Q2 2025 and -0.41% in Q1 2025.